The estimated Net Worth of Robert P Jr Roche is at least $493 Tisíc dollars as of 18 March 2016. Robert Roche owns over 50,000 units of Antares Pharma Inc stock worth over $492,881 and over the last 11 years Robert sold ATRS stock worth over $0.
Robert has made over 4 trades of the Antares Pharma Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Robert bought 50,000 units of ATRS stock worth $36,000 on 18 March 2016.
The largest trade Robert's ever made was buying 50,000 units of Antares Pharma Inc stock on 18 March 2016 worth over $36,000. On average, Robert trades about 2,600 units every 23 days since 2013. As of 18 March 2016 Robert still owns at least 88,172 units of Antares Pharma Inc stock.
You can see the complete history of Robert Roche stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300, EWING, NJ, 08628.
Over the last 12 years, insiders at Antares Pharma Inc have traded over $29,755,747 worth of Antares Pharma Inc stock and bought 910,400 units worth $1,278,090 . The most active insiders traders include James E Deerfield Mgmt L.P...., James E Deerfield Mgmt L.P.... a Jacques Gonella. On average, Antares Pharma Inc executives and independent directors trade stock every 28 days with the average trade being worth of $751,296. The most recent stock trade was executed by Anton Gueth on 8 July 2021, trading 100,000 units of ATRS stock currently worth $429,000.
Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.
Antares Pharma Inc executives and other stock owners filed with the SEC include: